Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats

Journal of Pharmacological Sciences

Volumn 123, Issue 1, 2013, Pages 58-66

  Yamazaki, Takanori ^a   Nakamura, Yasuhiro ^a   Shiota, Masayuki ^a   Osada Oka, Mayuko ^a,b   Fujiki, Hiroyuki ^c   Hanatani, Akihisa ^a   Shimada, Kenei ^a   Miura, Katsuyuki ^a   Yoshiyama, Minoru ^a   Iwao, Hiroshi ^a   Izumi, Yasukatsu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Acute myocardial infarction; Arginine vasopressin; Cardiac remodeling; Diuretic; Tolvaptan

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CHLORINE; CREATININE; FUROSEMIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; POTASSIUM; SODIUM; TOLVAPTAN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; GENE; GENE EXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART PROTECTION; IN VIVO STUDY; MALE; MCP 1 GENE; NONHUMAN; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; RAT; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; TNF ALPHA GENE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ACUTE-PHASE REACTION; ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBROSIS; FUROSEMIDE; HEART FAILURE; HEART VENTRICLES; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84887714810     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13086FP     Document Type: Article

References (30)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172. (Pubitemid 20119612)
2. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101:2981-2988. (Pubitemid 30415891)
3. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294. (Pubitemid 30026383)
4. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210. (Pubitemid 30451778)
5. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010;3:412-419.
6. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867. (Pubitemid 29131593)
7. Broqvist M, Dahlstrom U, Karlberg BE, Karlsson E, Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 1989;10:1075-1083. (Pubitemid 20031948)
8. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-1791. (Pubitemid 41579797)
9. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18. (Pubitemid 36851295)
10. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev. 2009;14:75-82.
11. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343. (Pubitemid 46513234)
12. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331. (Pubitemid 46513233)
13. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30:2233-2240.
14. Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, et al. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail. 2012;5:794-802.
15. Yamazaki T, Izumi Y, Nakamura Y, Hanatani A, Shimada K, Muro T, et al. Novel device that produces carbon dioxide mist for myocardial infarction treatment in rats. Circ J. 2012;76:1203-1212.
16. Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H. Anti-edematous effects of tolvaptan in experimental rodent models. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S77-S82.
17. Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, et al. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res. 2012;35:34-40.
18. Samukawa K, Izumi Y, Shiota M, Nakao T, Osada-Oka M, Miura K, et al. Red ginseng inhibits scratching behavior associated with atopic dermatitis in experimental animal models. J Pharmacol Sci. 2012;118:391-400.
19. Larsen FF. Haemodynamic effects of high or low doses of furosemide in acute myocardial infarction. Eur Heart J. 1988;9:125-131.
20. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159. (Pubitemid 46817812)
21. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540-1545.
22. Marti C, Cole R, Kalogeropoulos A, Georgiopoulou V, Butler J. Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators. Curr Heart Fail Rep. 2012;9:1-7.
23. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292. (Pubitemid 24333194)
24. Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res. 2004;27:771-779. (Pubitemid 40045517)
25. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432. (Pubitemid 38970186)
26. Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012;5:484-492.
27. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S67-S76.
28. Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:1322-1330.
29. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96:1046-1052.
30. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16 Suppl 1:S37-S44.